Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Alnylam Pharmaceuticals (GB:0HD2)
LSE:0HD2
Holding GB:0HD2?
Track your performance easily
See the Price Targets and Ratings of:
0HD2 Analyst Ratings
Moderate Buy
17 Buy
5 Hold
1 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
0HD2 Stock 12 Month Forecast
Average Price Target
$313.10
▲(28.01% Upside)
| Highest Price Target$400.00 | Average Price Target$313.10 | Lowest Price Target$205.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Leerink Partners
Reiterated
12/17/24
Piper Sandler
Reiterated
12/16/24
J.P. Morgan
Reiterated
11/27/24
Evercore ISI
Assigned
11/26/24
H.C. Wainwright
Reiterated
11/26/24
Scotiabank
Reiterated
11/26/24
Canaccord Genuity
Reiterated
11/25/24
Morgan Stanley
Reiterated
11/25/24
BMO Capital
Assigned
11/25/24
RBC Capital
Reiterated
11/25/24
TD Cowen
$371
Buy
51.68%
Upside
Assigned
11/19/24
TD Cowen Sticks to Its Buy Rating for Alnylam Pharma (ALNY)
Wolfe Research
$205
Sell
-16.19%
Downside
Downgraded
11/11/24
Alnylam downgraded to Underperform from Peer Perform at Wolfe ResearchAlnylam downgraded to Underperform from Peer Perform at Wolfe Research
Barclays
$295→$329
Buy
34.51%
Upside
Reiterated
11/01/24
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (NYSE: IQV), Alphatec Holdings (NASDAQ: ATEC) and Alnylam Pharma (NASDAQ: ALNY)
Oppenheimer
―
Hold
―
Reiterated
11/01/24
Alnylam Pharma (ALNY) Receives a Hold from Oppenheimer
Raymond James
$275→$298
Buy
21.83%
Upside
Reiterated
11/01/24
Alnylam price target raised to $298 from $275 at Raymond JamesAlnylam price target raised to $298 from $275 at Raymond James
Best Analysts Covering Alnylam Pharma
Which Analyst Should I Follow If I Want to Buy GB:0HD2 and Sell After:
1 Month
xxx
Success Rate
12/22 ratings generated profit
Average Return
+0.46%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 54.55% of your transactions generating a profit, with an average return of +0.46% per trade.
3 Months
xxx
Success Rate
18/30 ratings generated profit
Average Return
+5.90%
assigned a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +5.90% per trade.
1 Year
Success Rate
22/30 ratings generated profit
Average Return
+28.14%
assigned a buy rating last month
Copying Ritu Baral's trades and holding each position for 1 Year would result in 73.33% of your transactions generating a profit, with an average return of +28.14% per trade.
2 Years
xxx
Success Rate
32/37 ratings generated profit
Average Return
+39.21%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 86.49% of your transactions generating a profit, with an average return of +39.21% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
0HD2 Analyst Recommendation Trends
Rating
Aug 24
Sep 24
Oct 24
Nov 24
Dec 24
Strong Buy
5
2
2
5
4
Buy
36
37
60
50
36
Hold
15
12
16
14
13
Sell
0
0
0
1
1
Strong Sell
0
0
0
0
0
total
56
51
78
70
54
Each month's total comprises the sum of three months' worth of ratings.
0HD2 Financial Forecast
0HD2 Stock Forecast FAQ
What is GB:0HD2’s average 12-month price target, according to analysts?
Based on analyst ratings, Alnylam Pharmaceuticals’s 12-month average price target is $313.10.
What is GB:0HD2’s upside potential, based on the analysts’ average price target?
Alnylam Pharmaceuticals has 28.01% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Alnylam Pharmaceuticals a Buy, Sell or Hold?
Alnylam Pharmaceuticals has a consensus rating of Moderate Buy, which is based on 17 buy ratings, 5 hold ratings and 1 sell ratings.
What is Alnylam Pharmaceuticals’s share price target?
The average share price target for Alnylam Pharmaceuticals is $313.10. This is based on 23 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $400.00 ,and the lowest forecast is $205.00. The average share price target represents 28.01% Increase from the current price of $244.595.
The highest analyst share price target is $400.00 ,and the lowest forecast is $205.00. The average share price target represents 28.01% Increase from the current price of $244.595.
What do analysts say about Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 23 Wall Streets Analysts.
How can I buy shares of Alnylam Pharmaceuticals?
To buy shares of GB:0HD2, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.